
Following 16 weeks of rezpegaldesleukin treatment in the REZOLVE-AD study, primary and key secondary end points have been met.
Following 16 weeks of rezpegaldesleukin treatment in the REZOLVE-AD study, primary and key secondary end points have been met.
Dermocosmetics alongside traditional acne treatments improved skin tolerance and reduced acne severity in patients, particularly those using retinoids, leading to enhanced quality of life.
259 Prospect Plains Rd, Bldg H
Monroe, NJ 08831
© 2025 MJH Life Sciences®
All rights reserved.